Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder and CEO of activist hedge fund Starboard Value said. "We are having conversations with them and there are signs that Kenvue is already going in the right direction,

Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.

Tylenol, Listerine and Band-Aid maker Kenvue is the latest in the health related sector to attract an activist investor. And not just any corporate agitator, Starboard Value, which in recent days targeted pharma giant Pfizer.

Kenvue has a formidable lineup of well-known consumer health brands, such as Aveeno, Tylenol, Band-Aid, Zirtec, Listerine, and Neutrogena. These strong brand images can leverage the firm's growth and transformation of Kenvue.

Shares of consumer-products company Kenvue Inc. rose the most in more than two months after activist investor Starboard Value took a stake in the Tylenol maker with an eye toward making changes to boost the company’s stock price.

Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter. Starboard's Jeff Smith is expected to detail the position further at 13D Monitor’s Active-Passive Investor Summit on Tuesday.